<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081964</url>
  </required_header>
  <id_info>
    <org_study_id>PB-101-200</org_study_id>
    <nct_id>NCT01081964</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia</brief_title>
  <official_title>A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IASO Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IASO Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens
      of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a Phase 2, global, prospective, multi-dose, double-blind, double-dummy,
      active-control, randomized, parallel-group, multicenter study of oral zabofloxacin HCl
      (400mg) versus oral levofloxacin (500mg) in the treatment of adults with community-acquired
      pneumonia of moderate severity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Financial considerations
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 35 days after first dose</time_frame>
    <description>Assess safety through monitoring of adverse events, ECGs, and the collection of conventional laboratory data (i.e., chemistry panel, CBC with differential, urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the two dosing regimens of zabofloxacin</measure>
    <time_frame>Up to 35 days after first dose</time_frame>
    <description>Determine the clinical response and microbiological response of two dosing regimens in the treatment of bacteriologically confirmed CAP of moderate severity; determine the pharmacokinetic profile in subjects with CAP.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Community Acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Levofloxacin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500mg once daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zabofloxacin 5 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zabofloxacin 400mg for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zabofloxacin 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zabofloxacin 400mg for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin</intervention_name>
    <description>Zabofloxacin 400mg capsule once daily for 3 days</description>
    <arm_group_label>Zabofloxacin 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Levofloxacin 500mg orally for 7 days</description>
    <arm_group_label>Levofloxacin 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zabofloxacin 400mg</intervention_name>
    <description>Zabofloxacin 400mg orally for 5 days</description>
    <arm_group_label>Zabofloxacin 5 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;/= 18 years old

          -  Documented fever (oral &gt;100°F (37.8°C), tympanic &gt;101°F (38.1°C)must be documented
             within the time frame of 24 hours prior to first dose through 24 hours after first
             dose of study drug

          -  Community-acquired pneumonia of moderate severity (defined as PSI Risk Class II or
             III) requiring administration of antibiotics

          -  Dyspnea and/or tachypnea (&gt;20 breaths/minute)

          -  Clinical diagnosis of pneumonia, as demonstrated by all of the following signs and
             symptoms:

               1. new or increased cough

               2. production of purulent sputum or a change in the character of sputum in subjects
                  who normally have purulent sputum

               3. auscultatory findings on pulmonary examination of rales and/or evidence of
                  pulmonary consolidation (e.g., bronchial breath sounds, egophony, or dullness on
                  percussion)

          -  Females must be surgically sterile (e.g., tubal ligation, hysterectomy),
             post-menopausal at least 2 years, or if of childbearing potential, they must have a
             negative urine pregnancy test (β-human chorionic gonadotropin [β-hCG]) prior to
             randomization into the study. Males and females must agree that if they have
             intercourse that they will use at least two medically accepted methods of birth
             control (e.g., hormonal contraceptive, intrauterine device, spermicide, or condom)
             from study entry through 60 days after discontinuation of study drug treatment

          -  Able to give written informed consent in a manner approved by the Institutional Review
             Board or Ethics Committee and comply with the requirements of the study

        Exclusion Criteria:

        Subjects must NOT meet any of the following exclusion criteria:

          -  Received one or more doses of any systemic antibiotic in the last 2 weeks

          -  Diagnosed with any other infection requiring systemic antibacterial therapy

          -  Require long-term (&gt;7 days) antibiotic therapy

          -  Previous diagnosed condition that might mimic or complicate the course and evaluation
             of the infectious disease process (e.g., septic shock, bronchiectasis, lung abcess or
             empyema, aspiration pneumonia, active tuberculosis, pulmonary malignancy, cystic
             fibrosis, post-obstructive pneumonia, etc.)

          -  Hypothermia (oral &lt;96°F [35.6°C}, tympanic &lt;97°F [35.9°C]

          -  Hospitalization (inpatient) in the previous 60 days or infection presumably acquired
             in the hospital

          -  Resident of a skilled nursing facility anytime in the previous 60 days or infection
             presumably acquired in a skilled nursing facility

          -  Chronic infection with Hepatitis B

          -  Any evidence of, or is a known carrier of , Hepatitis C antibody

          -  Infection with Clostridium difficile

          -  Immunocompromising illness, including known human immunodeficiency virus (HIV)
             positivity or AIDS, organ (bone marrow) transplant recipients, and hematological
             malignancy

          -  Psychotic disease, peripheral neuropathy, and glucose-6-phosphate dehydrogenase
             deficiency; uncontrolled or poorly controlled diabetes. Diabetic subjects who are
             stable and on a stable course of antihyperglycemic agents for the past 3 months will
             be permitted in the trial.

          -  High exposure to sunlight or ultraviolet radiation

          -  Immunosuppressive therapy, including cancer chemotherapy or chronic use of
             corticosteroids (i.e., &gt;20mg prednisone or equivalent per day for &gt;/= 14 days within
             the last 6 months

          -  History of renal or hepatic disease as defined by at least one of the following:

               1. Calculated creatinine clearance &lt;50 mL/min (any subject on dialysis must be
                  excluded)

               2. BUN &gt;/= 30 mg/dL

               3. ALT or AST &gt; 3x ULN

               4. Total bilirubin &gt; 2x ULN

               5. Alkaline phosphatase &gt; 1.25x ULN

          -  History of or current malabsorption conditions (i.e., short bowel syndrome, active
             Crohn's disease, celiac disease, etc.)

          -  Neutropenia as defined by absolute neutrophil count &lt;1000 cells/mm3. Subjects with
             neutrophil counts as low as 500 cells/mm3 are permitted if the reduction can be
             documented to be due to the acute infectious process

          -  Platelet count &lt;75,000/mm3. Subjects with platelet counts as low as 50,000/mm3 are
             permitted if the reduction is historically stable

          -  Coagulation tests &gt;1.5x ULN (PT, PTT, or INR). Subjects on anticoagulants with values
             &gt; 1.5x ULN can be enrolled, provided these values are historically stable and within
             the therapeutic range

          -  History of alcohol or drug abuse in the past 2 years

          -  History of seizure or currently receiving anti-seizure medication anytime in the past
             year, or a seizure in the past year

          -  History of ventricular arrhythmia

          -  History of QTc prolongation (i.e., &gt;450msec) or observed QTc measurement at screening
             &gt; 450msec, or a history of additional risk factors for Torsade de Pointe, such as
             heart failure, hypokalemia, or familial history of Long QT syndrome

          -  Require medications that may prolong the QTc interval

          -  Require medications that affect absorption, including but not limited to sucralfate or
             cimetidine

          -  Require treatment with theophylline, probenecid, vitamin K antagonists (other than
             warfarin; subjects must be on stable dose of warfarin and within therapeutic range)

          -  Pregnant, planning to become pregnant, or breast feeding

          -  Received any investigational drug or device within 30 days prior to study entry

          -  Previously received zabofloxacin in a clinical trial

          -  History of allergy or intolerability to fluoroquinolones

          -  History of fluoroquinolone tendinopathy

          -  Evidence of immediately life-threatening disease including, but not limited to current
             or impending respiratory failure, acute heart failure, shock, acute coronary syndrome,
             unstable arrhythmias, hypertensive emergency, acute hepatic failure, active
             gastrointestinal bleeding, profound metabolic abnormalities (e.g., diabetic
             ketoacidosis), or acute cerebrovascular events

          -  Current condition or abnormality that, in the opinion of the investigator, would
             compromise the safety of the subject or the quality of the data

          -  Unable or unwilling to adhere to sthe study specified procedures and restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toney</city>
        <state>Alabama</state>
        <zip>35773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>93616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keego Harbor</city>
        <state>Michigan</state>
        <zip>48320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belvidere</city>
        <state>New Jersey</state>
        <zip>078238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <zip>18974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>Community acquired pneumonia of moderate severity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

